IL114852A - Pharmaceutically stable preparation of oxaliplatinum - Google Patents

Pharmaceutically stable preparation of oxaliplatinum

Info

Publication number
IL114852A
IL114852A IL11485295A IL11485295A IL114852A IL 114852 A IL114852 A IL 114852A IL 11485295 A IL11485295 A IL 11485295A IL 11485295 A IL11485295 A IL 11485295A IL 114852 A IL114852 A IL 114852A
Authority
IL
Israel
Prior art keywords
oxaliplatinum
pct
pharmaceutically stable
stable preparation
preparation
Prior art date
Application number
IL11485295A
Other languages
English (en)
Other versions
IL114852A0 (en
Inventor
Rolland-Yves Mauvernay
Houssam Ibrahim
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50845249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL114852(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of IL114852A0 publication Critical patent/IL114852A0/xx
Publication of IL114852A publication Critical patent/IL114852A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11485295A 1994-08-08 1995-08-07 Pharmaceutically stable preparation of oxaliplatinum IL114852A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH246294 1994-08-08

Publications (2)

Publication Number Publication Date
IL114852A0 IL114852A0 (en) 1995-12-08
IL114852A true IL114852A (en) 2000-02-29

Family

ID=50845249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11485295A IL114852A (en) 1994-08-08 1995-08-07 Pharmaceutically stable preparation of oxaliplatinum

Country Status (17)

Country Link
US (1) US5716988A (xx)
EP (1) EP0774963B1 (xx)
JP (1) JP3547755B2 (xx)
KR (1) KR100365171B1 (xx)
CN (1) CN1138541C (xx)
AT (1) ATE197249T1 (xx)
AU (2) AU2989695A (xx)
BR (1) BR9508554A (xx)
CA (1) CA2196922C (xx)
CZ (1) CZ286714B6 (xx)
DE (1) DE69519300T2 (xx)
DK (1) DK0774963T3 (xx)
ES (1) ES2152412T3 (xx)
IL (1) IL114852A (xx)
RU (1) RU2148400C1 (xx)
UA (1) UA42779C2 (xx)
WO (1) WO1996004904A1 (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2152412T3 (es) 1994-08-08 2001-02-01 Debiopharm Sa Preparacion farmaceuticamente estable de oxaliplatino.
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
CA2346564C (fr) * 1998-10-14 2011-05-03 Debiopharm S.A. Conditionnement d'une preparation d'oxaliplatine
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US7070796B1 (en) * 1999-08-30 2006-07-04 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation for parenteral administration
WO2001015691A1 (fr) * 1999-08-30 2001-03-08 Debiopharm S.A. Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale
US7012072B2 (en) * 2000-12-12 2006-03-14 Debiopharm S.A. Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same
WO2002069959A1 (fr) 2001-03-02 2002-09-12 Debiopharm S.A. Dispositif de conditionnement d'une solution d'oxaliplatine
EP1404689A1 (en) * 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
NZ545591A (en) * 2003-08-28 2008-11-28 Mayne Pharma Ltd Acid containing oxaliplatin formulations
US7576126B2 (en) * 2003-11-25 2009-08-18 Platco Technologies (Proprietary) Limited Platinum (II) complexes, preparation and use
CN100471493C (zh) * 2003-12-17 2009-03-25 梅比欧法姆股份有限公司 含有奥沙利铂的脂质体制剂
ES2393398T3 (es) * 2004-06-09 2012-12-21 Taiho Pharmaceutical Co., Ltd. Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
EP2011798B1 (en) * 2004-09-01 2011-06-29 Platco Technologies (Proprietary) Limited Preparation of platinum (II) complexes
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2007029268A2 (en) 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
CN101389637A (zh) * 2006-01-30 2009-03-18 普拉托技术(私有)公司 铂(ⅱ)配合物的制备
CA2647297A1 (en) * 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
AU2007247112B2 (en) 2006-05-09 2010-08-26 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
CN101588812A (zh) * 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
EP2152239A1 (en) * 2007-11-12 2010-02-17 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
CA2718233A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
DK2249825T3 (en) 2008-03-14 2016-01-11 Bionumerik Pharmaceuticals Inc Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
EP2481396A4 (en) 2009-09-21 2014-03-05 Jw Pharmaceutical Corp OXALIPLATIN NANOPARTICLES AND MANUFACTURING METHOD THEREFOR
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
AU2013202575B1 (en) * 2012-01-04 2013-05-16 Hospira, Inc. Dexmedetomidine premix formulation
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
JP5314790B1 (ja) * 2012-07-09 2013-10-16 東和薬品株式会社 オキサリプラチン含有医薬組成物
CN104703594B (zh) 2012-08-10 2018-01-23 大鹏药品工业株式会社 稳定的封装奥沙利铂的脂质体的水分散体及其稳定化方法
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
CN103690494B (zh) * 2013-11-29 2015-04-15 杭州华东医药集团新药研究院有限公司 一种低杂质含有奥沙利铂的组合物及其制备方法
KR101915452B1 (ko) 2014-06-23 2018-11-06 플라콘 테라퓨틱스 인코포레이티드 백금 화합물, 조성물 및 이의 용도
PL3865484T3 (pl) 2015-07-07 2024-04-22 H. Lundbeck A/S Inhibitor PDE9 ze szkieletem imidazopirazynonowym do leczenia chorób obwodowych
CN104940151A (zh) * 2015-07-23 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 一种抗癌药物奥沙利铂冻干粉针剂组合物
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US10987353B2 (en) 2016-05-04 2021-04-27 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
BR112019000005A2 (pt) 2016-07-06 2019-04-16 H. Lundbeck A/S inibidores de pde9 para o tratamento de doenças periféricas
CN115746003A (zh) 2017-05-26 2023-03-07 伊马拉公司 制备和使用pde9抑制剂的方法
KR20210014662A (ko) 2018-05-25 2021-02-09 이마라 인크. 6-[(3S,4S)-4-메틸-1-(피리미딘-2-일메틸)피롤리딘-3-일]-3-테트라히드로피란-4-일-7H-이미다조[1,5-a]피라진-8-온의 일수화물 및 결정형

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) * 1976-09-06 1985-09-13 喜徳 喜谷 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
IL83380A (en) * 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
NL8901433A (nl) * 1989-06-06 1991-01-02 Pharmachemie Bv Carboplatinpreparaat.
JPH04185601A (ja) * 1990-11-20 1992-07-02 Unitika Ltd 白金抗癌剤徐放性製剤
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート(トランス―1―1,2―シクロヘキサンジアミン)白金(▲ii▼)
AU5416394A (en) * 1992-11-24 1994-06-22 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
ES2152412T3 (es) 1994-08-08 2001-02-01 Debiopharm Sa Preparacion farmaceuticamente estable de oxaliplatino.

Also Published As

Publication number Publication date
DE69519300T2 (de) 2001-05-31
IL114852A0 (en) 1995-12-08
DK0774963T3 (da) 2001-01-29
CA2196922A1 (fr) 1996-02-22
EP0774963B1 (fr) 2000-11-02
EP0774963A1 (fr) 1997-05-28
AU2989695A (en) 2000-03-07
AU731981B2 (en) 2001-04-12
JP3547755B2 (ja) 2004-07-28
CZ286714B6 (en) 2000-06-14
DE69519300D1 (de) 2000-12-07
CZ37997A3 (en) 1997-06-11
ATE197249T1 (de) 2000-11-15
US5716988A (en) 1998-02-10
JPH10508289A (ja) 1998-08-18
UA42779C2 (uk) 2001-11-15
CN1154654A (zh) 1997-07-16
ES2152412T3 (es) 2001-02-01
KR970704434A (ko) 1997-09-06
RU2148400C1 (ru) 2000-05-10
BR9508554A (pt) 1997-11-25
AU2252499A (en) 2000-03-23
CA2196922C (fr) 2004-06-01
CN1138541C (zh) 2004-02-18
WO1996004904A1 (fr) 1996-02-22
KR100365171B1 (ko) 2003-02-19

Similar Documents

Publication Publication Date Title
IL114852A (en) Pharmaceutically stable preparation of oxaliplatinum
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
NO20023684D0 (no) Pediatrisk formulering
MXPA02008654A (es) Formulaciones de ranolazina de liberacion prolongada.
RU94040387A (ru) Композиция, способствующая прекращению курения, никотиносодержащий распыляемый раствор, способ снижения потребности в курении табака, способ замены курения табака
NO20054324L (no) Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
ES2007607A6 (es) Un procedimiento para la obtencion de un preparado de insulina para la administracion no parenteral.
AU2001288460A1 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
MY114389A (en) Aqueous risperidone formulations
HK1046090A1 (en) Use of l-carnitine and its alkanoyl derivatives asosmotic agents in solutions for medical use
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
GR3025742T3 (en) New pyrazine derivatives, their preparation and their use.
AU1852597A (en) Multifunctional fat absorption and blood cholesterol reducing formulation containing chitosan and nicotinic acid
DE502004002585D1 (de) Flüssige zubereitung enthaltend tobramycin
IL141232A0 (en) Use of camptothecin derivatives, with reduced gastrointestinal toxicity
NZ507407A (en) Stable mitoxantrone solutions
AU2001289762A1 (en) Pharmaceutical extemporary compositions
ZA988820B (en) Use of delta-aminolaevulinic acid for the preparation of a topical medicament for the integral diagnosis and/or therapy of tumours in hollow organs
HK1036413A1 (en) Solution comprising prostaglandins and benzyl alcohol.
Lin et al. Toxicity of a single oral dose of N-ethylphenylacetamide in rats
ES2125800A1 (es) Conjunto de infusion final.
MX9703839A (es) Soluciones intravenosas de lubeluzol.
ES2128966A1 (es) Composiciones farmaceuticas parenterales a base de calcitoninas sinteticas, de ph controlado, con bajo indice de dolor y buena estabilidad.
MY104837A (en) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
MX9708195A (es) Formulaciones para compuestos lipofilicos y uso de las mismas.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired